Pompey, France, 26 June 2013 - Novasep, a leading provider of purificationbased manufacturing solutions for life sciences molecules, today announces the appointment of Michel Spagnol as President and CEO of the company, effective from 25 June 2013. He will succeed Patrick Glaser, who after three years at Novasep in France, has decided to return to the USA. Michel Spagnol joins Novasep from Shasun, where he was President and Chief Technology Officer. He is a proven business leader with core expertise in leading contract manufacturing of active pharmaceutical ingredients and, more broadly, strong experience in using and developing innovative technologies to address needs of customers in fine chemicals and life sciences fields. Prior to Shasun Michel Spagnol spent his career at Rhodia in Lyon and Cranbury (NJ, USA) where he progressed first in technical R&D leadership roles and subsequently transitioned to business development as a Sales and Marketing Vice President of Rhodia Pharma Solutions.
Over the past months Novasep’s growth has gained momentum with significant new investments in Mourenx (France), to build the world’s largest chromatography plant dedicated to the pharmaceutical industry, in Le Mans (France) to expand manufacturing capabilities of cutting-edge anti-cancer therapies and in Shanghai (China) to better serve its clients in Asia. Roger-Marc Nicoud, Founder and Non-Executive Chairman of the Board of Novasep, said: “We are delighted to welcome Michel Spagnol to Novasep as CEO.His track record in delivering customer driven solutions, his international and scientific background coupled with his extensive management experience and longstanding knowledge and relationships in the pharmaceutical industry will be strong assets for the Company. He has all the qualities required to consolidate and accelerate Novasep’s development. On behalf of the Board, I would like to thank Patrick Glaser for his contributions as the CEO of the Company and accomplishments as Head of Novasep Synthesis. Over the past years, Novasep has grown significantly under his leadership, and he has developed a solid foundation for Michel Spagnol to build upon.”
Michel Spagnol, new CEO, declared: “Novasep is a world leader in purification technologies with differentiated capabilities in hazardous chemistry and high potency chemistry and is well positioned to serve the pharmaceutical, fine chemical, bio-pharma and industrial biotech industries. I am very pleased to be given the opportunity to lead the Company. I am looking forward to working closely with all my new colleagues. Novasep is on the right track for continued growth and expansion with promising projects which will enable us to continue delivering value-added solutions for our global customers.”
Biographical information on Michel Spagnol
Michel Spagnol graduated as a chemical engineer from the Mulhouse Engineering School (ENSC Mulhouse) in 1987, then moved to the US and completed his master and PhD at Stanford University in chemistry.
He joined the Rhône–Poulenc group (renamed Rhodia in 1998) in Lyon in 1993 where he successively held various senior managerial positions, with a strong focus in research management and then in sales and marketing functions. From 2000 to 2002, he was Innovation and Development Vice President at Rhodia Life Sciences Systems in Lyon. He then moved to the US in 2003, as Sales and Marketing Vice President at Rhodia Pharma Solutions. The main focus of his work at Rhodia was directed towards finding innovative and value-added solutions to answer customers’ needs, giving rise to 47 patents and publishing many articles in major journals.
In 2006, following the divestment of Rhodia Pharma Solutions to Shasun, he joined the new company as President and Chief Technology Officer. He successfully implemented a growth and profitable strategy for its Global CRAMS business.
Novasep is a global provider of cost-effective and sustainable solutions to produce active molecules at the required purity. Novasep's unique offering includes process development services, purification equipment and turnkey processes, contract manufacturing services and complex active molecules to serve pharmaceutical; biopharmaceutical; fine chemical; food and functional ingredients as well as bio-sourced chemicals and bio-industries.